Mortality during time on waiting list (ITT) · adult patients before and after liver transplantation.
It is very uncertain whether nutritional supplement (500ml) and standard diet changes mortality during time on waiting list (ITT) compared with standard diet alone (very low certainty).
1 finding from 1 review
Treatment‐related mortality at 1 year (mITT) · bullous pemphigoid
Doxycycline probably leads to lower treatment‐related mortality at 1 year (mITT) compared with prednisolone (moderate certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific mortality ‐ SJS and TEN (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
It is very uncertain whether corticosteroids changes disease‐specific mortality ‐ SJS and TEN (time to compared with no corticosteroids (very low certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease
Summary of findings: Defibrotide showed no clear difference in all‐cause mortality at 100 days post‐transplant ( compared with no treatment (low certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with haematological malignancies
It is very uncertain whether summary of findings: Glutamine changes all‐cause mortality at 100 days post‐transplant ( compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
Summary of findings: Ursodeoxycholic acid may leads to lower all‐cause mortality at 100 days post‐transplant ( compared with placebo or no treatment (low certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
Summary of findings: Heparin showed no clear difference in all‐cause mortality at 100 days post‐transplant ( compared with no treatment (low certainty).
1 finding from 1 review
Intervention not reported
Reported mortality, low risk of bias studies only · patients undergoing surgery
It is very uncertain whether the intervention changes reported mortality, low risk of bias studies only (very low certainty).
1 finding from 1 review
Intervention not reported
Inpatient mortality 2640 participants (10 studies)
The intervention showed no clear difference in inpatient mortality 2640 participants (10 studies) (low certainty).
1 finding from 1 review
In‐hospital mortality at 30 days or at the longest · critically ill patients 18 years or older treated for respiratory failure or septic or both, cardiogenic or haemorrhagic shock who resided…
It is very uncertain whether physical and cognitive therapy changes in‐hospital mortality at 30 days or at the longest compared with standard care (very low certainty).
1 finding from 1 review
All‐cause mortality ‐ short term (end of treatment) · health problem or population
It is very uncertain whether summary of findings table ‐ Pharmacological treatment 1 changes all‐cause mortality ‐ short term (end of treatment) compared with pharmacological treatment 2 (very low certainty).
1 finding from 1 review
Intervention not reported
Maternal morbidity, neonatal morbidity or mortality · mixed population (women with a fear of childbirth; women with high levels of anxiety; husbands of pregnant women; pregnant women and…
The intervention probably leads to lower maternal morbidity, neonatal morbidity or mortality (moderate certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Six months mortality after liver transplantation (ITT) · adult patients before and after liver transplantation.
It is very uncertain whether nutritional supplement (500ml) and standard diet changes six months mortality after liver transplantation (ITT) compared with standard diet alone (very low certainty).
1 finding from 1 review
Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found